Canada Clinical Trial Authorizations
Before a drug trial can start in Canada, Health Canada has to authorize it with a No Objection Letter. Its database lists every authorized trial since 2013 and the company behind each one, including trials that never appear in US registries.
All 9,774 drug trials Health Canada has authorized since 2013, through Nov 13, 2026, with each trial's sponsor, investigational products and conditions.
- Authorized, last 12 months: 683
- Ongoing: 4,563
- Authorized since 2013: 9,774
Trials authorized per year
By the date of Health Canada's No Objection Letter.
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
- Full year
- 2013 to date
Top sponsors, 2024 to 2026
Company groups, by the products' Canadian sponsor.
Top conditions, 2024 to 2026
As Health Canada lists them; a trial can have several.
- Non-small cell lung cancer63
- Advanced solid tumors55
- Solid tumors55
- Overweight/obesity52
- Ulcerative colitis41
- Atopic dermatitis39
- Alzheimer's disease35
- Obesity34
- Asthma31
- Crohn's disease29
Every authorized trial
The last two years, newest first; searching or filtering loads every trial since 2013. Sponsors with FDA records link to their company page.1,426 trials
| Nov 13, 2026 | Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis orโฆDM-101PX ยท Seasonal allergic rhinitis ยท Rhinoconjuctivitis ยท Protocol DM-101-C-006 (C2D07557) | Desentum Oy | Pending |
| Nov 13, 2026 | A phase 3 randomized, double-blind, placebo-controlled, multicenter study to determine the efficacy and safety of ulviprubart in the treatment of participantsโฆUlviprubart (ABC008) ยท Inclusion body myositis ยท Protocol ABC008-IBM-301 | Abcuro Inc | Pending |
| Nov 13, 2026 | A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, andโฆEPRA-0322 ยท Anemia ยท Chronic kidney disease (CKD) ยท Protocol EPK-0322-101 (5863-04) | Epok Therapeutics Inc. | Pending |
| Nov 13, 2026 | A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in participants with rheumatoid arthritisMK-8690 ยท Rheumatoid arthritis ยท Protocol MK-8690-004 | Merck & Co. (MSD) | Pending |
| Nov 13, 2026 | Dualis: a modular phase I/ii, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, andโฆAZD1221 ยท Hematological malignancies ยท Protocol D7920C00001 | AstraZeneca Pharmaceuticals | Pending |
| Nov 13, 2026 | A phase 3 randomized open-label study to evaluate the safety and efficacy of risvutatug rezetecan in combination with atezolizumab in participants with newlyโฆRisvutatug rezetecan (GSK5764227) ยท Small cell lung cancer ยท Protocol 300599 | GSK | Pending |
| Nov 12, 2026 | Hidradenitis suppurativa: a phase 2 multicenter platform study of targeted therapies for the treatment of adult subjectsABBV-295 / Lutikizumab (ABT-981) ยท Hidradenitis suppurativa ยท Protocol M26-508 | AbbVie | Pending |
| Nov 10, 2026 | A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, andโฆCSL787 ยท Non-cystic fibrosis bronchiectasis ยท Protocol CSL787_2001 | CSL | Pending |
| Nov 6, 2026 | A phase 1 open-label, multicenter study to evaluate the safety, tolerability and pharmacokinetics of MK-1568 as monotherapy in participants with metastaticโฆMK-1568 ยท Prostate cancer metastatic castrationโฆ ยท Protocol MK-1568-001 | Merck & Co. (MSD) | Pending |
| Nov 5, 2026 | An investigation of the effect of subcutaneous zenagamtide on pharmacokinetics of an oral combination contraceptive (ethinylestradiol and levonorgestrel) andโฆZenagamtide (NNC0487-0111) / Portia (ethinyl estradiol / Levonorgestrel) /โฆ ยท Overweight/obesity ยท Protocol NN9490-8154 | Novo Nordisk | Pending |
| Nov 5, 2026 | An open-label, phase 1b study to evaluate the safety of VERVE-301 in patients with elevated lipoprotein(a)VERVE-301 (LY4354070) ยท Elevated levels of lipoprotein ยท Protocol VT-30101 | Verve Therapeutics, Inc., A Wholly Owned Subsidiary of Eli Lilly and Company | Pending |
| Nov 3, 2026 | A rollover study to evaluate the safety, tolerability, and efficacy of long-term trontinemab administration in participants with Alzheimer's diseaseTrontinemab (RO7126209) / Lantheus ([18F]MK-6240) ยท Alzheimer's disease ยท Protocol WN45890 | Roche | Pending |
| Oct 30, 2026 | A phase 2/3 multi-arm, open-label study of MK-1045 in combination with zilovertamab vedotin in participants with relapsed/refractory diffuse large B-cellโฆMK-1045 / Zilovertamab vedotin (MK-2140) ยท Diffuse large B-cell lymphoma ยท Protocol MK-1045-010 | Merck & Co. (MSD) | Pending |
| Oct 30, 2026 | Solara: a phase 3 study of the efficacy and safety of sutacimig in participants with Glanzmann thrombastheniaSutacimig (HMB-001) ยท Glanzmann thrombasthenia ยท Protocol HMB-001-103 | Hemab Therapeutics Inc. | Pending |
| Oct 30, 2026 | A phase 3 study evaluating sacituzumab tirumotecan plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) as induction therapy, followed byโฆMK-2870 / Keytruda sc (MK-3475A) ยท Muscle-invasive bladder cancer ยท Protocol MK-2870-055 | Merck & Co. (MSD) | Pending |
| Oct 30, 2026 | An open-label, rollover study for participants with thyroid eye disease previously enrolled in amgen-sponsored amg 732 studies and are primary proptosisโฆAmg 732 ยท Thyroid eye disease ยท Protocol 20230294 | Amgen | Pending |
| Oct 30, 2026 | A phase 3, randomized, double-masked, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics,โฆKlygefa (gefurulimab (ALXN1720)) ยท Myasthenia gravis ยท Protocol ALXN1720-OMG-303 | AstraZeneca Pharmaceuticals | Pending |
| Oct 29, 2026 | A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects withโฆTelisotuzumab adizutecan (ABBV-400) / Gemcitabine ยท Pancreatic cancer ยท Biliary cancer ยท Protocol M26-118 | AbbVie | Pending |
| Oct 29, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sotatercept in adults with combined postcapillary andโฆWinrevair (sotatercept (MK-7962)) ยท Pre- and post-capillary pulmonaryโฆ ยท Heart failure ยท Protocol MK-7962-041 | Merck & Co. (MSD) | Pending |
| Oct 29, 2026 | A phase 3 multicenter, randomized, open-label study evaluating the safety and efficacy of etentamig (ABBV-383) compared to daratumumab, cyclophosphamide,โฆEtentamig (ABBV-383) ยท Amyloidosis ยท Protocol M24-473 | AbbVie | Pending |
| Oct 28, 2026 | Endeavor: a clinical study to evaluate the safety and efficacy of ETX101, an AAV9-delivered gene therapy in infants and children with SCN1A-positive DravetโฆETX101 ยท Dravet syndrome ยท Protocol ETX-DS-002 | Encoded Therapeutics, Inc. | Pending |
| Oct 27, 2026 | Luna-2: a phase II randomized trial of LND101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy inโฆLND101 ยท Non-small cell lung cancer ยท Protocol BR.39 | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Pending |
| Oct 23, 2026 | A randomised, double-blind, placebo-controlled phase IIa trial to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of biโฆBI 3810477 ยท Idiopathic pulmonary fibrosis (IPF) ยท Protocol 1530-0005 | Boehringer Ingelheim (Canada) Ltd Ltee | Pending |
| Oct 23, 2026 | A phase 1-1b study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177lu]LU-A9-0631 and [225ac]AC-A9-0642 in participants withโฆ[177LU]LU-A9-0631 injection / [225AC]AC-A9-0642 injection / [68GA]GA-A9-6217โฆ ยท Tumor ยท Protocol A9-0600-01 | ALPHA-9 Oncology USA Inc. | Pending |
| Oct 23, 2026 | Master protocol: MK-2870-U01 master protocol: a phase 1/2 platform study to evaluate the safety and efficacy of sacituzumab tirumotecan (sac-tmt; MK-2870) asโฆMK-2870 (sacituzumab tirumotecan) / Opevesostat (MK-5684) / Abiraterone acetateโฆ ยท Prostate cancer ยท Protocol MK-2870-U01 | Merck & Co. (MSD) | Pending |
| Oct 22, 2026 | A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,โฆRybrevant (AMIVANTAMAB0 ยท Squamous cell carcinoma of the head andโฆ ยท Protocol 61186372HNC3002 | Johnson & Johnson | Pending |
| Oct 22, 2026 | A multicnter, randomized, double-blind, placebo controlled program consisting of a phase 2b trial and phase 3 trial to evaluate the efficacy and safety ofโฆTEV-53408 ยท Vitiligo ยท Protocol TV53408-IMM-30105 | Teva Canada Limited | Pending |
| Oct 22, 2026 | Rosetta LUNG-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants withโฆPumitamig (BMS-986545; BNT327) ยท Non-small cell lung cancer ยท Protocol CA2660020 | Bristol-Myers Squibb | Pending |
| Oct 21, 2026 | A global, interventional, open-label trial of t-dxd-based therapy followed by palbociclib, endocrine therapy and dual HER2 blockade in first-line HER2+/HR+โฆEnhertu / Arimidex / Aromasin / Faslodex / Femara / Ibrance / Perjeta / Herzumaโฆ ยท Breast cancer HER2-positive ยท Breast cancer metastatic ยท Protocol DS8201-0004-CIS-MA | Daiichi Sankyo | Pending |
| Oct 20, 2026 | A phase 3, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone versus standard available therapyโฆInobrodib (CCS1477) / Pomalidomide / Dexamethasone / Darzalex (daratumumab) /โฆ ยท Multiple myeloma ยท Protocol CCS1477-05 | Cellcentric Ltd | Pending |
| Oct 16, 2026 | A phase 1b/2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of MK-2750 monotherapy in participants withโฆMK-2750 ยท Advanced solid tumors ยท Protocol MK-2750-002 | Merck & Co. (MSD) | Pending |
| Oct 16, 2026 | A phase 3, open label, randomized study comparing the efficacy and safety of odronextamab (REGN1979), an ANTI-CD20 ร ANTI-CD3 bispecific antibody, inโฆOdronextamab (REGN1979) ยท Diffuse large B-cell lymphoma ยท Protocol R1979-ONC-2105 | Regeneron | Pending |
| Oct 16, 2026 | Novel endovascular therapy with bevacizumab and cannabinoids for glioblastomaAvastin / Sativex / Osmitrol injection 20% ยท Glioblastoma ยท Protocol NOVA-GBM-PH1-001 | St Michaels Hospital | Pending |
| Oct 15, 2026 | A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, EGFR wildtype, locallyโฆTelisotuzumab adizutecan (ABBV-400) ยท Non-small cell lung cancer ยท Protocol M26-167 | AbbVie | Pending |
| Oct 15, 2026 | An open-label randomized phase 2 study to evaluate safety and efficacy of patritumab deruxtecan plus pembrolizumab administered either before or afterโฆPatritumab deruxtecan (MK-1022) / Pembrolizumab (MK-3475) ยท Breast cancer ยท Protocol MK-1022-010 | Merck & Co. (MSD) | Pending |
| Oct 14, 2026 | A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of zigakibart in pediatric patients with primaryโฆZigakibart (FUB523) ยท Immunoglobulin A nephropathy ยท Protocol CFUB523B12301 | Novartis Pharmaceuticals | Pending |
| Oct 14, 2026 | A phase I/ib, multi-center, open-label, dose escalation and dose expansion study of FVY281 as monotherapy in adult participants with relapsed/refractory acuteโฆFVY281 / Azacitidine ยท Acute myeloid leukemia ยท Protocol CFVY281A12101 | Novartis Pharmaceuticals | Pending |
| Oct 13, 2026 | Investigating the interplay between faah and opioid misuse in chronic non-cancer pain (CNCP): positron emission tomography studies with [11c]curb[11C]CURB ยท Pain ยท Protocol CAMHPET-CTA-153 | Centre for Addiction and Mental Health | Ongoing |
| Oct 9, 2026 | Actfirst: a phase III, open-label, multi-center, randomized study comparing AAA817+arpi versus standard of care in adult participants with psma-positiveโฆ[225AC]AC-PSMA-617 (AAA817) / Zytiga / Xtandi ยท Prostate cancer metastatic castrationโฆ ยท Protocol CAAA817B12301 | Novartis Pharmaceuticals | Pending |
| Oct 9, 2026 | A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable NSCLC (stage iii) who haveโฆIvonescimab ยท Non-small cell lung cancer ยท Protocol SMT112-3010 | Summit Therapeutics Inc. | Pending |
| Oct 2, 2026 | A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standardโฆAZD6750 ยท Chronic hepatitis B ยท Protocol D7351C00001 | AstraZeneca Pharmaceuticals | Pending |
| Oct 2, 2026 | A phase 2/3 multicenter, randomized, open-label study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in theโฆASP-1929 (CETUXIMAB-IR700) ยท Squamous cell carcinoma of the head andโฆ ยท Protocol ASP-1929-381 | Rakuten Medical, Inc. | Pending |
| Oct 1, 2026 | A phase 3 registrational study to assess the efficacy, safety and tolerability of OCU410 for geographic atrophy secondary to dry age-related macularโฆOCU410 (adeno-associated viral vector 5 human rora (AAV5-HRORA)) ยท Wet age-related macular degeneration ยท Protocol OCU410-301 | Ocugen, Inc | Pending |
| Oct 1, 2026 | Volatile anesthetic pharmacokinetics during extracorporeal membrane oxygenationSevoflurane ยท Acute respiratory distress syndromeโฆ ยท Protocol 22-6007 | University Health Network | Pending |
| Oct 1, 2026 | Bridge study: buprenorphine xr real-world induction, dosing, and gradual evaluationBuprenorphine ยท Opioid use disorder ยท Protocol HREBA.CTC-26-0111 | Dr. Navneet Singh Khosa | Pending |
| Oct 1, 2026 | A randomized trial of RIPK2 inhibitor OD-001 in combination with vedolizumab for moderately to severely active ulcerative colitisOD-001 (OD-07656) / Vedolizumab ยท Ulcerative colitis ยท Protocol OD-001-202 | Odyssey Therapeutics | Pending |
| Oct 1, 2026 | A phase 1 safety and feasibility trial of focused ultrasound for the treatment of high-grade glioma in patients undergoing standard chemotherapy (GB7260)Perflutren (perfluoropropane) ยท Glioblastoma ยท Protocol GB-7260 | Sunnybrook Research Institute | Pending |
| Sep 29, 2026 | A two-part, phase 2b/phase 3 double-blinded, randomized study of IPN60340 in combination with azacitidine and venetoclax versus placebo in combination withโฆIPN60340 ยท Acute myeloid leukemia ยท Protocol CLIN-60340-450 | Ipsen | Pending |
| Sep 29, 2026 | A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of LP-003 in peanut allergyโฆLP-003 / Peanut powder / Oat powder ยท Penicillin allergy ยท Protocol P10-LP003-10 | Longbio Pharma (Suzhou) Co., Ltd | Ongoing |
| Sep 28, 2026 | A phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study with an open-label treatment period to evaluate the efficacy andโฆAGN-151607-DP (gemibotulinumtoxina) ยท Major depressive disorder ยท Protocol M26-083 | AbbVie | Pending |
Phase I to III drug trials Health Canada authorized with a No Objection Letter since April 2013; device and natural health product trials are not in the database, and it gives no phase. The sponsor is the company named on the trial's investigational products. Search a protocol number on Health Canada's site for its sites and contacts. Refreshed weekly. Health Canada, Clinical Trials Database